Softwr

Research · head to head

Dotmatics vs Remesh

Dotmatics logo

Dotmatics

Research

Research informatics group behind GraphPad Prism, SnapGene, Geneious and LabArchives, now owned by Siemens

From
On request
Rated
-
Full reviewWebsite
Remesh logo

Remesh

Research

Live AI-moderated conversations with hundreds of participants at once, analysed in real time

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Dotmatics the portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.; Remesh pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
  • They diverge on capability: Dotmatics covers Dotmatics platform, Remesh covers Live moderated sessions.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Dotmatics and Remesh actually diverge.

Attributes where Dotmatics and Remesh differ
AttributeDotmaticsRemesh
PlatformsWeb, Windows, macOS, On-premiseWeb, API

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Dotmatics

  • Dotmatics platform
  • GraphPad Prism
  • SnapGene
  • Geneious Prime and Biologics
  • LabArchives
  • Flow cytometry tools
  • Protein Metrics
  • Siemens ownership

Only in Remesh

  • Live moderated sessions
  • Collective dialogue
  • Flex asynchronous studies
  • Video research
  • Remy AI assistant
  • On-Demand Recruit
  • Real-time theme analysis
  • Practice sessions

What people use each for

The jobs each tool is most often brought in to do.

Dotmatics

  • A pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layernot Remesh
  • A biotech that already owns Prism, SnapGene and Geneious separately and wants to understand what a group contract would covernot Remesh
  • A university licensing LabArchives across departments as an institutional electronic lab notebooknot Remesh
  • A biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement routenot Remesh

Remesh

  • A brand team that needs to test three positioning statements with 400 target customers and know by the end of the day which one lands and with whomnot Dotmatics
  • An HR function running an employee listening session across several thousand staff where anonymity and volume both matternot Dotmatics
  • A public affairs team needing rapid citizen consultation on a policy option with evidence of how widely each objection is heldnot Dotmatics
  • An insights team that has to replace six focus groups with one session because fieldwork time has been cut and the decision cannot waitnot Dotmatics

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Dotmatics

  • The portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.
  • The Siemens acquisition completed in July 2025 with stated revenue synergy targets, which usually translates into pressure to move individually bought desktop licences into larger platform agreements, and small buyers of a single Prism or SnapGene seat should expect that pressure at renewal.
  • Nothing about the enterprise platform is publicly priced, and even the individual applications are increasingly moved to subscription, so total cost across a research group is hard to establish before negotiation.
  • Each acquired product retains its own licence terms, support channel and release cycle, so an organisation using four Dotmatics brands manages four different renewal dates, entitlement models and support experiences.
  • Enterprise deployments require data migration and configuration services, and validated instances for regulated use add both cost and an ongoing customer revalidation duty after each release, so the informatics platform is a programme rather than a purchase.

Remesh

  • Pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
  • The public review picture is inconsistent in a way worth investigating: a small number of positive buyer reviews on G2 sit alongside a poor Trustpilot rating driven mostly by participant complaints, so ask directly how participants are recruited and compensated before running a study on your own customers.
  • Funding has slowed sharply, from a 25 million USD round in 2021 to a 4.25 million USD round in late 2022, so procurement teams at large organisations should expect to run a vendor viability review.
  • The collective dialogue mechanic rewards views that many participants recognise and vote for, which systematically under-weights genuinely novel minority insight, so it is a poor fit for exploratory discovery work where the outlier is the point.
  • The discussion guide builder, especially spreadsheet import, is reported as unreliable, and because sessions are live with recruited participants a tooling failure during setup is expensive rather than merely annoying.

Pricing, plan by plan

Dotmatics

On request
  • Dotmatics platform$undefined/year
    • Enterprise informatics platform priced per user per year on quotation
    • Chemistry and biology registration, assay data and ELN modules scoped separately
    • Implementation and data migration services quoted as a separate programme

Remesh

On request
  • Remesh$undefined/year
    • Live moderated sessions
    • Flex asynchronous studies
    • Video research

Which should you pick?

Choose Dotmatics if

  • You need dotmatics platform.
  • You work on Web, Windows, macOS, On-premise.
  • You also want graphpad prism.
Dotmatics review

Choose Remesh if

  • You need live moderated sessions.
  • You work on Web, API.
  • You also want collective dialogue.
Remesh review

Questions people ask

Is Dotmatics or Remesh better?
Neither clearly leads. Dotmatics starts at On request and Remesh at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Dotmatics or Remesh?
Dotmatics starts at On request and Remesh at On request.
Does Dotmatics or Remesh run on more platforms?
Dotmatics runs on Web, Windows, macOS, On-premise. Remesh runs on Web, API.
What is Dotmatics best used for?
Dotmatics is most often used for a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer, a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover, a university licensing labarchives across departments as an institutional electronic lab notebook, a biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement route. Of those, a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer and a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover are not what Remesh is typically brought in for.
What can Dotmatics do that Remesh cannot?
Dotmatics covers Dotmatics platform, GraphPad Prism, SnapGene, Geneious Prime and Biologics. Remesh covers Live moderated sessions, Collective dialogue, Flex asynchronous studies, Video research.

Answered from the vendors’ own pages

Dotmatics: Who owns Dotmatics?

Siemens, which completed a 5.1 billion dollar acquisition on 1 July 2025. Dotmatics now sits inside Siemens Digital Industries Software.

Remesh: How many people can join one session?

Sessions are designed for several hundred participants at once, which is the core reason to choose it over a conventional focus group.

Dotmatics: Is GraphPad Prism a Dotmatics product?

Yes. So are SnapGene, Geneious, LabArchives, FCS Express, OMIQ, Protein Metrics, SoftGenetics and nQuery.

Remesh: Does it publish pricing?

No. Contracts are quoted annually, typically scoped by session volume, and third-party estimates place them in the tens of thousands of dollars per year.

Dotmatics: Do the products work together?

To varying degrees. They were acquired separately and integration across the portfolio is uneven, so verify the specific pair you care about before assuming it.

Remesh: Can it replace a survey?

Not entirely. It produces open-ended language with agreement percentages, which is stronger than a survey for understanding reasoning but weaker for precise population estimates.

Dotmatics: Is enterprise pricing published?

No. The informatics platform is quoted per user per year with modules and services scoped separately.

Remesh: Does Remesh recruit participants for me?

Yes, through On-Demand Recruit, typically delivering a panel within about 24 hours, or you can bring your own list.

Share

Related pages

More on Dotmatics

More on Remesh

Keep looking

Other head to heads